AcuamarkDx: Pioneering a Transformative Approach to Early Cancer Diagnostics

AcuamarkDx is pioneering a transformative approach to early cancer diagnostics with its proprietary qPCR and methylation-based technology. qPCR is the tool of choice used by hospitals and clinics to diagnose infectious diseases.

The company's mission is to make early cancer detection as accessible and reliable as routine primary care diagnostics, establishing a new standard for accurately identifying cancer signals in blood at ultra-low abundance levels. By focusing on detecting cancer at its earliest stages—often before it becomes clinically visible—AcuamarkDx’s technology has the potential to significantly improve patient outcomes, enabling treatments when intervention is most

effective.

AcuamarkDx’s innovative platform leverages a two-step qPCR process combined with advanced machine learning models to detect and analyze methylation markers that are crucial indicators of cancer. This method offers a detailed and precise analysis of cancer signals in blood samples, with the capability to distinguish malignant from indolent cancers and identify the tumor's tissue of origin. AcuamarkDx’s methylation panels are among the highest performing in the industry, but at the same time, they are designed for high-volume testing that integrates smoothly into clinical workflows.

Currently, AcuamarkDx is developing and validating panels for colorectal cancer (CRC) recurrence and early detection, as well as broader multi-cancer monitoring solutions. In recent clinical testing, Acuamark’s top machine learning models achieved an impressive 92% sensitivity and 97% specificity across stages I-IV of cancer, underscoring the platform’s potential to revolutionize cancer care with robust and reliable instrumentation such as qPCR. The company is preparing manuscripts for publication and peer review.

AcuamarkDx’s breakthrough technology offers an accurate, reliable, accessible, and high-margin solution for patients, healthcare providers, and the broader industry, with the potential to drastically reduce the human and economic burden associated with late-stage cancer care.

At the heart of AcuamarkDx’s story is a team of seasoned experts in life sciences, genetic detection, and biotechnology. The leadership team, including scientific co-founders who are pioneers in genetic detection and sequencing innovations, brings decades of experience in biotech, diagnostics, bio-analytics and clinical development. Collectively, they hold more than 170 issued U.S. patents in foundational technologies widely used across the industry. This strong foundation of expertise positions AcuamarkDx as a critical player in the multi-billion-dollar cancer diagnostics market, with plans to expand globally through an IVD kit development strategy, making early cancer detection more widely available and impactful.